Recent advances in managing gastrointestinal stromal tumor [version 1; referees: 2 approved]
Florence Duffaud, Axel Le Cesne
F1000Research · 2017
doi:10.12688/f1000research.11118.1 (opens in a new tab)
We email you when a new notice or a question about this paper appears.
Abstract
Constitutive activating mutations in KIT and platelet-derived growth factor receptor α (PDGFRα) are heavily involved in the pathobiology of gastrointestinal stromal tumors (GISTs). This disease has served as an effective “proof-of-concept” model for targeting gain-of-function kinase mutations in cancer. This review discusses the current standard of care in terms of pharmacotherapy in the management of localized and metastatic GISTs.
Abstract licence: CC BY
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.